News | September 18, 2009

Accumetrics Reviews Meta-analysis Anti-Platelet Therapy After PCI at TCT

September 18, 2009 – Patients’ response to anti-platelet therapy after percutaneous coronary intervention (PCI) and its impact on clinical outcomes will be covered in a TCT 2009 breakfast symposium starting at 6:30 a.m. Wedensday, Sept. 23 in room 121 at the Moscone Center in San Francisco.

The session will help participants gain an understanding of the landscape of oral antiplatelet therapy in 2010 and review options of assessing response in antiplatelet therapy, and review the impact of platelet reactivity on clinical outcomes via a comprehensive meta-analysis.

The presentation includes:

• 7 a.m. – “Landscape of Oral Antiplatelet Therapy 2010,” presented by George Dangas, M.D., Ph.D.

• 7:10 a.m. – “Impact of Platelet Reactivity on Clinical Outcomes: A Meta-Analysis,” presented by
Somjot Brar, M.D.

• 7:25 a.m. – Case reviews and discussion moderator - George Dangas. Discussants include Germano Di Sciascio, Franz-Josef Neumann, M.D., Somjot Brar

• 7:50 a.m. – Discussion with audience questions

• 8 a.m. – Adjourn

The sponsor of the event is Accumetrics, maker of the VerifyNow System, which offers physician’s high level clinical data regarding their patient’s anti-platelet medications within minutes with an in-office test. The VerifyNow System assesses response to life-saving anti-platelet therapies, such as aspirin, Plavix, Effient and GP IIb/IIIa inhibitors. Patients respond to anti-platelet medications differently and these tests help physicians ensure their patients are receiving the optimal treatment.

For more information: www.accumetrics.com

Related Content

Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Overlay Init